Literature DB >> 12620613

Cannabis use for chronic non-cancer pain: results of a prospective survey.

Mark A Ware1, Crystal R Doyle, Ryan Woods, Mary E Lynch, Alexander J Clark.   

Abstract

There has been a surge in interest in medicinal cannabis in Canada. We conducted a questionnaire survey to determine the current prevalence of medicinal cannabis use among patients with chronic non-cancer pain, to estimate the dose size and frequency of cannabis use, and to describe the main symptoms for which relief was being sought. Over a 6-week period in mid-2001, 209 chronic non-cancer pain patients were recruited in an anonymous cross-sectional survey. Seventy-two (35%) subjects reported ever having used cannabis. Thirty-two (15%) subjects reported having used cannabis for pain relief (pain users), and 20 (10%) subjects were currently using cannabis for pain relief. Thirty-eight subjects denied using cannabis for pain relief (recreational users). Compared to never users, pain users were significantly younger (P=0.001) and were more likely to be tobacco users (P=0.0001). The largest group of patients using cannabis had pain caused by trauma and/or surgery (51%), and the site of pain was predominantly neck/upper body and myofascial (68% and 65%, respectively). The median duration of pain was similar in both pain users and recreational users (8 vs. 7 years; P=0.7). There was a wide range of amounts and frequency of cannabis use. Of the 32 subjects who used cannabis for pain, 17 (53%) used four puffs or less at each dosing interval, eight (25%) smoked a whole cannabis cigarette (joint) and four (12%) smoked more than one joint. Seven (22%) of these subjects used cannabis more than once daily, five (16%) used it daily, eight (25%) used it weekly and nine (28%) used it rarely. Pain, sleep and mood were most frequently reported as improving with cannabis use, and 'high' and dry mouth were the most commonly reported side effects. We conclude that cannabis use is prevalent among the chronic non-cancer pain population, for a wide range of symptoms, with considerable variability in the amounts used. Discussions between patients and health care providers concerning cannabis use may facilitate education and follow up, and would allow side effects and potential interactions with other medications to be monitored. Clinical trials of cannabis for chronic non-cancer pain are warranted.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12620613     DOI: 10.1016/s0304-3959(02)00400-1

Source DB:  PubMed          Journal:  Pain        ISSN: 0304-3959            Impact factor:   6.961


  41 in total

Review 1.  [Cannabinoids--signal transduction and mode of action].

Authors:  R Rukwied; B Gauter; M Schley; C Konrad
Journal:  Schmerz       Date:  2005-11       Impact factor: 1.107

2.  Exploring the ecological association between crime and medical marijuana dispensaries.

Authors:  Nancy J Kepple; Bridget Freisthler
Journal:  J Stud Alcohol Drugs       Date:  2012-07       Impact factor: 2.582

3.  Prescribing marijuana for chronic pain.

Authors:  Roger Ladouceur
Journal:  Can Fam Physician       Date:  2015-08       Impact factor: 3.275

Review 4.  In the weeds: a baseline view of cannabis use among legalizing states and their neighbours.

Authors:  Rosalie Liccardo Pacula; Mireille Jacobson; Ervant J Maksabedian
Journal:  Addiction       Date:  2016-01-26       Impact factor: 6.526

Review 5.  The pharmacotherapy of chronic pain: a review.

Authors:  Mary E Lynch; C Peter N Watson
Journal:  Pain Res Manag       Date:  2006       Impact factor: 3.037

6.  A randomized, placebo-controlled, crossover trial of cannabis cigarettes in neuropathic pain.

Authors:  Barth Wilsey; Thomas Marcotte; Alexander Tsodikov; Jeanna Millman; Heather Bentley; Ben Gouaux; Scott Fishman
Journal:  J Pain       Date:  2008-04-10       Impact factor: 5.820

7.  Low-dose vaporized cannabis significantly improves neuropathic pain.

Authors:  Barth Wilsey; Thomas Marcotte; Reena Deutsch; Ben Gouaux; Staci Sakai; Haylee Donaghe
Journal:  J Pain       Date:  2012-12-11       Impact factor: 5.820

8.  Prevalence and determinants of cannabinoid prescription for the management of chronic noncancer pain: a postal survey of physicians in the Abitibi-Témiscamingue region of Quebec.

Authors:  Huguette St-Amant; Mark A Ware; Nancy Julien; Anaïs Lacasse
Journal:  CMAJ Open       Date:  2015-04-02

9.  Molecular mechanisms involved in the asymmetric interaction between cannabinoid and opioid systems.

Authors:  Daniela Viganò; Tiziana Rubino; Angelo Vaccani; Silvia Bianchessi; Patrick Marmorato; Chiara Castiglioni; Daniela Parolaro
Journal:  Psychopharmacology (Berl)       Date:  2005-10-19       Impact factor: 4.530

10.  Relief-oriented use of marijuana by teens.

Authors:  Joan L Bottorff; Joy L Johnson; Barbara M Moffat; Tamsin Mulvogue
Journal:  Subst Abuse Treat Prev Policy       Date:  2009-04-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.